Neglected Tropical Diseases (NTDs)

The Challenge

  • Lymphatic filariasis (LF) – commonly known as elephantiasis – affects over 120 million people and is a threat to nearly 1.4 billion people in more than 70 countries.
  • Although the disease is not life-threatening, the disability and the incapacitating acute attacks caused by LF often leave infected persons unable to work, which can lead to or exacerbate conditions of poverty.

HKI Solution

  • HKI is one of 40 members of the Global Alliance to Eliminate Lymphatic Filariasis, which aims to eliminate LF as a public health problem by 2020 and to alleviate the physical, social and economic hardship that individuals who have LF-induced disability face.
  • We work to eliminate LF in eight countries in Africa and Asia. For example, in Burkina Faso, HKI has integrated LF control activities into its onchocerciasis control program. With our partners, FDC/Save the Children U.S. and Handicap International, HKI works with the national program in regions where LF prevalence rates reach 72%.
  • In Sierra Leone, the treatment of LF is being integrated into Community-Directed Treatment with Ivermectin (CDTI) nationwide: 30,000 Community Directed Distributors are now distributing both ivermectin and albendazole to treat both onchocerciasis and LF.